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Abstract
Background: The purpose of this study was to design a brief questionnaire to measure fears about
recurrence and health in cancer survivors. Research involving fear of recurrence has been
increasing, indicating that it is an important concern among cancer survivors.
Methods: We developed and tested a six-item instrument, the Assessment of Survivor Concerns
(ASC). Construct validity was examined in a multiple group confirmatory factor analysis (CFA) with
592 short-term and 161 long-term cancer survivors. Convergent and discriminant validity was
examined through comparisons with the PANAS (Positive and Negative Affect Schedule) and the
CES-D (Center for Epidemiologic Studies Depression) measures.
Results: CFA models for the ASC with short- and long-term survivors showed good fit, with
equivalent structure across both groups of cancer survivors. Convergent and discriminant validity
was also supported through analyses of the PANAS and CES-D. One item (children's health worry)
did not perform as well as the others, so the models were re-run with the item excluded, and the
overall fit was improved.
Conclusion: The ASC showed excellent internal consistency and validity. We recommend the
revised five-item instrument as an appropriate measure for assessment of cancer survivor worries.
Background
As treatments and detection for cancer improve, life
expectancy for cancer survivors is longer than it has ever
been before. While this is of course a welcome develop-
ment, there are potential concerns that need to be
addressed. One of these is the constant fear experienced
by many cancer survivors that their cancer will return.
While the risk of recurrence varies considerably depend-
ing on the cancer type, tumor characteristics, and stage at
diagnosis, many cancers do return, generally in the first
few years following diagnosis, but sometimes even after
many years of remission. Fear of cancer recurrence is recog-
nized as having significant negative psychological conse-
quences, and researchers have recently taken a greater
interest in the construct. Lee-Jones et al. provided an
important review of the work that had been done in this
area up to 1997 [1].
Northouse reported the first work on the development of
a scale specific for measuring fear of cancer recurrence, the
22-item Northouse Fear of Recurrence Scale [2]. The scale
was developed for the purpose of testing a hypothesized
relationship between the availability of significant others
and reduced fear of recurrence. Northouse reported that
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the scale had adequate reliability, and later studies using
the scale also found adequate reliability, but validity
assessment was not performed [3,4].
Other early measures of fear of cancer recurrence include
the Worry about Cancer Scale [5] and the Fear of Recur-
rence Index [5,6]. The Worry about Cancer Scale was
based on cognitive-behavioral theory, and focused on per-
ceptual cues that could elicit worry. The Fear of Recurrence
Index was developed to test the relation between type of
surgery and fear of recurrence.
More recently, Vickberg (2003) developed the 29-item
Concerns About Recurrence Scale (CARS) [7], which
assesses the extent and nature of women's fears about the
possibility of breast cancer recurrence. The CARS was
found to be internally consistent, and exploratory factor
analysis revealed four worry factors: health, womanhood,
role, and death.
As part of a more comprehensive study assessing quality
of life in adult long-term cancer survivors, Avis et al.
(2005) developed the 47-item Quality of Life in Adult
Cancer Survivors (QLACS) [8]. The participants in this
study were all five years or more post-diagnosis. Through
exploratory factor analysis, the QLACS was shown to be a
multi-dimensional instrument with 12 subscales. One of
the subscales is characterized as "recurrence distress" and
contains four items related to fear of recurrence. Another
is characterized as "family distress" and contains three
items related to fear of family members getting cancer.
Both subscales showed adequate reliability and criterion-
based validity. These data suggest that fear of cancer recur-
rence is a distinct and important construct that should be
studied further.
The purpose of this study was to develop and evaluate a
brief (only six items) instrument, which is specific to two
factors: fear of cancer recurrence and fear of health issues
in general. It was not intended to assess overall quality of
life, but rather to serve as an adjunct – or module – to
other quality of life questionnaires. Also, in contrast to
previous research, which has used exploratory analyses,
we tested a theoretical model of fear of recurrence through
confirmatory factor analysis. Further, because fear of can-
cer recurrence has the potential to be defined differently
between survivors who are at different points post-diag-
nosis, we included both long-term (5–6 years post-diag-
nosis) and short-term (1.5–2.5 years post-diagnosis)
cancer survivors in this study.
Based on interviews and comments on open-ended ques-
tions in previous research with cancer survivors, we devel-
oped six items for the instrument (see Table 1), which was
named the Assessment of Survivor Concerns (ASC). Three
items (recurrence, new diagnosis, diagnostic tests) were
specific to cancer worry (forming a cancer worry sub-
scale), and three (death, health, and children's health)
assessed general health worry (forming a health worry
subscale).
In an assessment of construct validity, the cancer specific
and the general health constructs were hypothesized to be
distinct, but with variance in common. Additionally,
because worry is a form of distress, both constructs were
hypothesized to be related to, but distinct from, other neg-
ative affect constructs (e.g., depression). In an assessment
of convergent validity, we predicted that cancer and health
worry would be significantly correlated with negative
affect measures. We hypothesized that this correlation
should not be very large in magnitude since the cancer
and health worry constructs were seen as distinct from
other negative affect constructs. Also, in an assessment of
discriminant validity, we predicted that cancer and health
worry would have small or zero correlations with meas-
ures of positive affect. If both convergent and discrimi-
nant validity were found, this would provide further
evidence in support of construct validity.
In this paper, when we refer to all six items as a whole, we
will use the qualifiers questionnaire or instrument. When
referring to either the three cancer specific items or to the
three general health items, we will use the qualifier sub-
scale. When referring to a particular item, we will use the
Table 1: Cancer Worry Questionnaire Correlations
I t e m I  w o r r y  a b o u t . . . S u b s c a l e 123456
1 future diagnostic tests Cancer Worry 1.00
2 another type of cancer Cancer Worry 0.81 1.00
3 my cancer coming back Cancer Worry 0.76 0.87 1.00
4 dying Health Worry 0.33 0.31 0.28 1.00
5 my health Health Worry 0.34 0.35 0.33 0.58 1.00
6 my children's health Health Worry 0.31 0.31 0.30 0.27 0.38 1.00
Each item had a Likert-type scale with four response options: 1 = Not at all; 2 = A little bit; 3 = Somewhat; 4 = Very much. All correlations are 
statistically significant at the 0.0001-level.Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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qualifier item. Additionally, we use the terms construct and
factor interchangeably when referring to the latent con-
structs (e.g., cancer worry and health worry) that are
assessed by the observed items.
Methods
Participants
Cancer survivors were identified through the population-
based Hawaii Tumor Registry (HTR), a member of the
National Cancer Institute-supported Surveillance, Epide-
miology, and End Results (SEER) Registry, which main-
tains records for all cancers diagnosed in the state.
Eligibility criteria were histologic confirmation of cancer
diagnosed 1.5–2.5 years prior to assessment (short-term
survivors) or 5–6 years prior to assessment (long-term sur-
vivors), localized stage of disease, cancer-free status at
time of assessment, ability to understand English, permis-
sion of primary physician, Hawaii residency, and at least
18 years of age.
There were 1,323 survivors identified who met the eligi-
bility criteria. These individuals were mailed a question-
naire packet, and the items reported in this paper were
among a number of scales of quality of life and well-
being. Institutional Review Board approval was obtained.
We did not obtain written informed consent. The ele-
ments of informed consent were included in a covering
letter, and return of the survey indicated consent. A total
of 753 patients returned questionnaires for an overall
response rate of 57%. Response rates were comparable for
the 161 long-term (54%) and 592 short-term (58%) sur-
vivors. See Table 2 for demographic and clinical character-
istics by response status. See Table 3 for demographic and
clinical characteristics of the final sample by survivor sta-
tus.
Measures
The primary measure was the newly developed ASC ques-
tionnaire, consisting of six items. These items were devel-
oped based on comments from cancer survivors in
previous studies of quality of life, in which we asked what
was missing in available questionnaires; cancer recurrence
and health fears were frequent responses. Candidate items
were pretested in cancer survivors in support groups and
semi-structured interviews (approximately 20 individu-
als), who reported that all six candidate items were rele-
vant and clearly phrased. The instrument was divided into
two subscales with three items each. The first subscale's
items were specific to cancer worry (recurrence, new diag-
nosis, and diagnostic tests), and the second subscale's
items were related to general health worry (death, health,
and children's health). See Table 1 for a list of all the ques-
tionnaire items along with inter-item correlations, and see
Table 4 for the means, standard deviations, and distribu-
tions of responses.
Two instruments were used for the assessment of conver-
gent and discriminant validity for the cancer and health
worry subscales. The first was the Positive and Negative
Affect Schedule (PANAS), which assesses both pleasurable
and distressful mood states [9]. The original PANAS
instrument consisted of 20 items, but we only included
10. These 10 items have been tested psychometrically,
shown to be useful in previous research [10], and previ-
ously used with cancer patient populations [11,12]. Five
of these 10 items (excited, enthusiastic, determined, alert,
and inspired) reflect positive affect, and five (upset, dis-
tressed, nervous, scared, and afraid) reflect negative affect.
The second instrument was the Center for Epidemiologic
Studies Depression (CESD) scale, which has been used
extensively in both community and patient populations,
Table 2: Demographic and clinical characteristics by response 
status
Responders Non-responders Total
n% n % n %
Age
Under 50 117 15.5 116 20.4 233 17.6
50–65 293 38.9 200 35.1 493 37.3
Over 65 343 45.6 254 44.6 597 45.1
Sex
Female 494 65.6 360 63.2 854 64.6
Male 259 34.4 210 36.8 469 35.4
Marital Status*
With Partner 524 69.6 346 60.7 870 65.8
No Partner 221 29.3 219 38.4 440 33.3
Ethnicity*
Japanese 321 42.6 213 37.4 534 40.4
Caucasian 248 32.9 153 26.8 401 30.3
Hawaiian 100 13.3 112 19.6 212 16.0
Filipino 79 10.5 84 14.7 163 12.3
Other 5 0.7 9 1.6 14 1.1
Treatment
Surgery 688 91.4 522 91.6 1210 91.5
Chemotherapy 92 12.2 60 10.5 152 11.5
Radiation 300 39.8 192 33.7 492 37.2
Hormone 160 21.2 95 16.7 255 19.3
Site*
Breast 296 39.3 173 30.4 469 35.4
Digestive 108 14.3 83 14.6 191 14.4
Prostate 101 13.4 69 12.1 170 12.8
Other 248 32.9 245 43.0 493 37.3
Total 753 100.0 570 100.0 1323 100.0
For Treatment, responses are not mutually exclusive. Statistically 
significant differences (p < .01) are indicated with an asterisk (*).Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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Table 3: Demographic and clinical characteristics by survivor status
Short-Term Survivors Long-Term Survivors Total Sample
n%n % n %
Age*
Under 50 87 14.7 30 18.6 117 15.5
50–65 209 35.3 84 52.2 293 38.9
Over 65 296 50.0 47 29.2 343 45.6
Sex*
Female 372 62.8 122 75.8 494 65.6
Male 220 37.2 39 24.2 259 34.4
Marital Status
With Partner 413 69.8 100 62.1 513 68.1
No Partner 179 30.7 61 37.9 240 31.2
Ethnicity
Japanese 233 39.4 74 46.0 307 40.8
Caucasian 198 33.5 45 28.0 243 32.3
Hawaiian 70 11.8 19 11.8 89 11.8
Filipino 59 10.0 14 8.7 73 9.7
Other 32 5.4 9 5.6 32 5.4
Children
None 98 16.6 27 16.8 125 16.6
One 78 13.2 19 11.8 97 12.9
Two 160 27.0 52 32.3 212 28.2
Three 98 16.6 30 18.6 128 17.0
Four or More 156 26.4 30 18.6 186 24.7
Education
No Degree 69 11.7 11 6.9 80 10.7
High School 131 22.2 29 18.2 160 21.4
Some College 193 32.8 56 35.2 249 33.3
College Degree 127 21.6 34 21.4 161 21.5
Graduate Degree 69 11.7 29 18.2 98 13.1
Family Income
Under $25,000 173 31.4 45 28.7 218 30.8
$25,000–$50,000 174 31.6 42 26.8 216 30.5
Over $50,000 204 37.0 70 44.6 274 38.7
Treatment
Surgery 465 78.6 133 82.6 598 79.4
Chemotherapy* 82 13.9 39 24.2 121 16.1
Radiation* 262 44.3 87 54.0 349 46.4
Hormone 96 16.2 25 15.5 121 16.1
Site*
Breast 222 37.5 78 48.4 300 39.8
Digestive 92 15.5 15 9.3 107 14.2
Prostate 84 14.2 16 9.9 100 13.3
Female Genital 59 10.0 19 11.8 78 10.4
Other 135 22.8 33 20.5 168 22.3
Total 592 78.6 161 21.4 753 100.0
Only data from the final sample are shown. For Treatment, responses are not mutually exclusive. Statistically significant differences (p < .01) are 
indicated with an asterisk (*).Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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Table 4: Cancer Worry Questionnaire Response Distributions, Means, and Standard Deviations by Survivor Status
Cancer Worry Subscale Health Worry Subscale
Future Tests New Cancer Recurrence Death Health Children's Health
n%n% N % n % n % n %
Short-term
1-Not at all 169 28.5 148 25.0 163 27.5 418 70.6 290 49.0 313 52.9
2-A little bit 103 17.4 107 18.1 110 18.6 116 19.6 194 32.8 105 17.7
3-Somewhat 108 18.2 107 18.1 102 17.2 28 4.7 75 12.7 37 6.3
4-Very much 186 31.4 201 34.0 196 33.1 13 2.2 19 3.2 24 4.1
No Response 26 4.4 29 4.9 21 3.5 17 2.9 14 2.4 113 19.1
Mean/S.D. 2.55 1.20 2.64 1.18 2.58 1.19 1.37 0.68 1.69 0.82 1.52 0.84
Long-term
1-Not at all 38 23.6 32 19.9 39 24.2 116 72.0 70 43.5 72 44.7
2-A little bit 33 20.5 32 19.9 30 18.6 30 18.6 55 34.2 32 19.9
3-Somewhat 39 24.2 36 22.4 34 21.1 7 4.3 23 14.3 25 15.5
4-Very much 47 29.2 57 35.4 57 35.4 5 3.1 12 7.5 5 3.1
No Response 4 2.5 4 2.5 1 0.6 3 1.9 1 0.6 27 16.8
Mean/S.D. 2.61 1.11 2.75 1.12 2.69 1.16 1.37 0.72 1.86 0.93 1.72 0.90
Total Sample
1-Not at all 207 27.5 180 23.9 201 26.7 534 70.9 360 47.8 385 51.1
2-A little bit 136 18.1 139 18.5 140 18.6 146 19.4 249 33.1 137 18.2
3-Somewhat 148 19.7 143 19.0 137 18.2 35 4.6 98 13.0 62 8.2
4-Very much 232 30.8 258 34.3 253 33.6 18 2.4 31 4.1 29 3.9
No Response 30 4.0 33 4.4 22 2.9 20 2.7 15 2.0 140 18.6
Mean/S.D. 2.56 1.18 2.67 1.17 2.60 1.19 1.37 0.69 1.73 0.85 1.57 0.86
For the response distributions for each item, the number of people (n) is shown on the left-hand side and the percentage (%) on the right. For the 
means and standard deviations (S.D.), the mean is on the left and the standard deviation is on the right.
including cancer patients [13-15]. It includes 20 symp-
tom-related four-point items, in which respondents rate
the frequency of having experienced these symptoms dur-
ing the past week. Sixteen of the items are worded to
reflect negative affect (depression), and four (felt good,
future hopeful, happy, enjoyed life) are worded to reflect
positive affect.
Data analysis
Assessment of the construct validity of the ASC instru-
ment across the two survivor groups (long- and short-
term) was provided using a multiple-group confirmatory
factor analysis (CFA) with Jöreskog and Sörbom's LISREL
8.7 software [16]. See Figure 1 for the hypothesized
model. This approach allowed for a comprehensive
assessment of measurement invariance [17-22] across the
two groups. Complete measurement invariance would
imply that the two groups are identical for every aspect of
cancer worry.
Results
Missing values
Before the analyses were performed, an examination of
missing values was conducted. For the six-item ASC, the
number of missing values were 30, 33, 22, 20, 15, and 140
for the items diagnostic tests, another cancer, recurrence,
death, health, and children's health, respectively. The
larger number of missing of values for the children's
health item was a result of several individuals not having
children (see Table 2). For the PANAS and CES-D instru-
ments, there were 52 and 74 individuals, who did not
respond to at least one item on the respective instruments.
All subsequent analyses were performed with both list-
wise and pairwise deletion of missing values. However,
listwise deletion was our preferred method and the pair-
wise deletion analyses were only performed for compara-
tive purposes. After listwise deletion of missing values
there were data from 454 short-term and 126 long-term
survivors.
In order to assess whether or not the missing values were
missing at random, we created six dummy variables, one
for each of the six cancer worry items. If the cancer worry
item was missing, then the corresponding dummy item
was coded a one; if not missing, then a zero. Models were
then run to assess whether there were statistically signifi-
cant relations between the dummy variables and theHealth and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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demographic, clinical, cancer worry, PANAS, and CES-D
variables.
As expected, missing values on the children's health item
were related to marital status and number of children
(people without partners or without children were more
likely to skip the item). Additionally, people who were
older, of lower income, and less educated, were more
likely to skip the three cancer worry items (recurrence,
new diagnosis, and diagnostic tests). This suggests that
generalizations of the cancer worry subscale to older,
lower income, and less educated populations should be
made only with caution, and further research involving
these groups is needed.
Reliability
As assessment of the reliability (internal consistency),
coefficient alpha was computed for the cancer worry and
health worry subscales. Alpha was equal to 0.93 and 0.63,
respectively. The values were equivalent (to two decimal
places) for the listwise and pairwise deletion of missing
value methods. This suggested that the cancer worry sub-
scale had excellent reliability, but that the health worry
subscale was in need of improvement.
Check for violations of underlying assumptions
The sample was checked for multivariate outliers by calcu-
lating the Mahalanobis distance [23] (the distance from
the multivariate centroid of the six items) for each person.
With an α = .001 cutoff level (chosen to ensure a low risk
of false outliers), no multivariate outliers were found.
Multivariate normality was assessed by calculating the
normalized estimate of Mardia's multivariate kurtosis
coefficient [24]. This coefficient was equal to 31.7 (p <
.0001), indicating that the variables were not distributed
with multivariate normality.
Additionally, models were run to assess nonlinear rela-
tions between the six items. The square of each item was
calculated and used to predict the remaining items in sep-
arate regression models. For example, in one model recur-
rence worry was the outcome, and the predictors were
death worry and the square of death worry. The square of
death worry variable indicated if there were a nonlinear
relation between death worry and recurrence worry. In all
models (15 total), no statistically significant nonlinear
relations (p < .01) were found.
Because the data were ordinal and not distributed with
multivariate normality, two methods were used to esti-
mate the model parameters and fit. First, the standard
method of maximum likelihood (ML) estimation [16]
incorporating the covariance matrix and means from both
groups was run. Second, the diagonally weighted least
squares (DWLS) method with the polychoric correlation
matrices [16,25] for each group was run. DWLS also
Confirmatory Factor Models for the Six-Item and Five-Item ASC Instruments Figure 1
Confirmatory Factor Models for the Six-Item and Five-Item ASC Instruments. Note. All values are standardized. 
The numbers on the top are for the original six-item ASC; and the numbers on the bottom are for the revised five-item ASC 
(children's health item excluded).Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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required an estimate of the asymptotic covariance matrix
of the sample correlations for each group. Both the poly-
choric correlation matrices and the asymptotic covariance
matrices were calculated with Jöreskog and Sörbom's PRE-
LIS software [26]. Although the standard ML method has
been shown to be fairly robust under violation of the mul-
tivariate normality assumption, the DWLS method is pre-
ferred when violations are severe [25]. We compared the
results from both methods to determine whether or not
the different methods led to different conclusions.
Goodness-of-fit indices
For assessments of model fit, we chose three goodness-of-
fit indices: the root mean square error of approximation
(RMSEA), the comparative fit index (CFI), and the non-
normed fit index (NNFI; also called the Tucker-Lewis
index, TLI) [27]. For the RMSEA, values less than .06 are
considered indicative of good model fit. For the CFI and
NNFI, good fit is implied by values greater than .90 [27].
We also examined χ2 values for purposes of assessing
improvement in model fit across nested models. When
models are nested (identical in structure, but differing in
the number of free parameters) the change in χ2, ∆χ2,
across the models provides a significance test for improve-
ment in model fit (the degrees of freedom for the compar-
ison is equal to the difference in degrees of freedom across
the models). If a less restricted model does not show
improved fit over a more restricted one, then the more
parsimonious restricted model is the appropriate one. If
the less restricted model does have significantly improved
fit, then the restricted model must be abandoned.
The overall χ2 test, which tests the null hypothesis of per-
fect model fit, was also reported because of its ubiquitous
reporting in the confirmatory factor analytic literature.
However, because of its sensitivity to sample size, this test
is generally considered to be an appropriate measure only
when the total sample size is less than 200 [28]. Further,
this test is affected by the correlations between the varia-
bles in the model, with higher correlations suggesting
poorer fit. The present analyses have a sample size greater
than 200 and the correlations within the model were
expected to be fairly high (because all variables were
hypothesized to reflect worry). Therefore, the χ2 test was
not viewed as an appropriate fit index for the present
study, except when comparing nested models.
Measurement invariance
Five separate nested CFA models were run, with each sub-
sequent model adding restrictions to the differences
allowed across the two groups. The first model tested form
(pattern) invariance between the two groups [17-22]. If
form invariance is indicated, it implies that the hypothe-
sized model is valid for both groups (construct validity is
demonstrated for both groups), and that both groups
have the same overall structure (in the path model, the
same directional arrows are valid for each group). Results
showed support for form invariance (see Table 5, original
six-item models). All three fit indices were in the range of
good fit.
In the second model, the factor loading slopes were con-
strained across the groups (called slope or weak factorial
invariance). If this restricted model were supported, it
would indicate that for both groups the influence of the
latent constructs on the observed items is equivalent. The
∆χ2 test (see Table 5, original six-item models) indicated
that the original (form invariant) model did not have sta-
Table 5: Maximum likelihood goodness-of-fit indices for confirmatory factor models
Original Six-Item ASC
Invariance χ2 df p ∆χ2 df p RMSEA CFI NNFI
Form 32.0 16 .01 .055 .992 .985
Slope 33.7 22 .05 1.7 6 .95 .038 .994 .992
Intercept 39.9 28 .07 6.2 6 .40 .035 .994 .994
Item Error 46.1 34 .08 6.2 6 .40 .033 .994 .995
Covariance 46.5 35 .09 0.4 1 .53 .033 .994 .995
Revised Five-Item ASC (children's health item excluded)
Invariance χ2 df p ∆χ2 df p RMSEA CFI NNFI
Form 11.2 8 .19 .033 .998 .996
Slope 15.8 13 .26 4.6 5 .47 .024 .999 .998
Intercept 21.4 18 .26 5.6 5 .35 .015 .999 .998
Item Error 30.5 23 .14 9.1 5 .11 .030 .996 .997
Covariance 30.9 24 .16 0.4 1 .53 .029 .997 .997
χ2 is the chi-square value for the given model with degrees of freedom, df, and probability, p. ∆χ2 is the difference in chi-square between the given 
model and the previous one. RMSEA is the Root Mean Square Error of Approximation, CFI is the Comparative Fit Index, and NNFI is the Non-
Normed Fit Index. Listwise deletion of missing values was used for all of the models.Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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tistically significantly improved fit over the slope invari-
ant model. Therefore the slope invariant model was more
appropriate.
In the third model, the factor loading slopes and inter-
cepts were constrained across the groups (called intercept
or strong factorial invariance). If this restricted model
were supported, it would indicate that both groups not
only have the same slopes, but also the same means on
the latent constructs. The ∆χ2 test (see Table 5, original six-
item models) indicated that the slope invariant model did
not have improved model fit over the intercept (plus
slope) invariant model. Therefore the intercept (plus
slope) invariant model was more appropriate.
In the fourth model, in addition to constraining the factor
loading slopes and intercepts, the item error variances
were constrained across the groups (called item error or
strict factorial invariance). If this restricted model were
supported, it would indicate that both groups not only
have the same slopes and intercepts, but also the same
item error variances. The ∆χ2 test (see Table 5, original six-
item models) indicated that the intercept (plus slope)
invariant model did not have improved model fit over the
item error invariant model. Therefore the item error invar-
iant model was more appropriate.
Finally, in the fifth model, in addition to all the con-
straints in the item error invariant model, the latent cov-
ariances (the covariance between the cancer worry and
health worry factors) were constrained across the groups
(called latent covariance invariance). If this restricted
model were supported, it would indicate that both groups
not only have the same slopes, intercepts, and item error
variances, but also the same latent covariances. The ∆χ2
test (see Table 5, original six-item models) indicated that
the item error (plus slope and intercept) invariant model
did not have improved model fit over the latent covari-
ance invariant model. Therefore the latent covariance
invariant model was more appropriate.
In the latent covariance invariant model, all possible
parameters were constrained across the two groups.
Because this model was shown to be the best one, it can
be concluded that both long- and short-term survivors
have identical structure and complete measurement invar-
iance with respect to the cancer and health worry con-
structs (as measured by the six items developed here). See
Figure 1 for the standardized parameter estimates. The
correlation between the cancer and health worry con-
structs was .47, confirming our hypothesis that the con-
structs were related but distinct.
Alternate analyses
In order to assess issues of missing values and violations
of multivariate normality, we examined the results when
performing the analyses using pairwise deletion of miss-
ing values, and when using the DWLS estimation method.
Fortunately, when using DWLS the goodness-of-fit indices
were all on the side of the threshold that indicated good
model fit, indicating that the maximum likelihood
method provided unbiased results. However, when pair-
wise deletion of missing values was used, results were not
the same as with listwise deletion. Specifically, when
using pairwise deletion, the three health worry items
(death, health, and children's health) exhibited neither
intercept invariance nor item error invariance across the
long- and short-term survivor groups. The long-term sur-
vivors had a higher mean on the health worry construct
than the short-term survivors did.
These differences across the listwise and pairwise deletion
methods were most influenced by missing values on the
children's health item. This item had substantially more
missing values than the other items due to several individ-
uals not having children. With listwise deletion, all people
with no children were excluded from the analyses, but
with pairwise deletion they were not. The differences in
the results across the listwise and pairwise deletion meth-
ods suggest the possibility that long-term survivors with
no children had higher scores on the health worry factor
than short-term survivors with no children. For people
with children (listwise deletion results), however, no dif-
ferences across survivor groups were found. For the cancer
worry factor, the results were unchanged across the list-
wise and pairwise deletion methods, suggesting that this
construct was equivalent for both people with and with-
out children.
Because of these issues with the children's health item, for
comparative purposes, we reran each of the models with
this item excluded. Missing values were handled with the
listwise deletion method, and the resulting samples sizes
were 546 short-term survivors and 152 long-term survi-
vors. The conclusions were unchanged from when the
item was included. Form, slope, intercept, item error, and
covariance invariance were all still supported (see Table 5,
revised five-item models). This suggests that a revised five-
item ASC (with the children's health item excluded) is
preferable to the original six-item instrument. The five-
item model showed virtually the same level of construct
validity (as demonstrated by the confirmatory factor mod-
els), and was free of the missing value problems resulting
from the children's health item. Additionally, the coeffi-
cient alpha for the two-item health worry subscale was
0.72 (this is compared to 0.63 for the three-item sub-
scale).Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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Convergent and discriminant validity
As a further assessment of construct validity, assessments
of convergent and discriminant validity were made for
both the original six-item ASC and the revised five-item
ASC (children's health item excluded). Correlations
between the cancer and health worry subscales, and the
PANAS (positive and negative subscales) and CESD were
calculated. Scores for each of the subscales were computed
as the mean of the set of items representing the given sub-
scale. If a person had missing values on some, but not all,
of the items for a given subscale, then the mean was calcu-
lated from the items that were available. Computed sub-
scale scores were only missing if all of the representative
items were missing. Because the short- and long-term sur-
vivor groups were found to be equivalent (complete meas-
urement invariance), separate correlations by group were
not necessary.
For the assessment of convergent validity, we set the crite-
rion that the cancer and health worry subscales would cor-
relate with the PANAS Negative subscale and the CES-D,
and be statistically significant at the 0.001-level. For the
assessment of discriminant validity, we set the criterion
that the cancer and health worry subscales would not cor-
relate with the PANAS Positive subscale (not statistically
significant at the 0.001-level). The correlations between
the two ASC subscales and the PANAS (positive and neg-
ative) and CES-D are shown in Table 6. Results for both
the original six-item ASC and the revised five-item ASC are
shown. Convergent validity was clearly demonstrated, as
all were statistically significant at the .001-level, with cor-
relations ranging from .19 (cancer worry and CES-D) to
.46 (health worry and PANAS Negative). The highest
value of .46 indicated that 20% of the variance is shared is
between health worry and PANAS Negative. This value is
not considerably high, suggesting that cancer worry and
health worry are related to, but distinct from, negative
affect measures.
Discriminant validity was also shown, especially between
health worry and PANAS Positive (r = .02, p = 0.67). The
correlation between cancer worry and PANAS positive was
nearly statistically significant at the 0.001-level (p  =
0.003), but the magnitude of effect was small (r = 0.11,
only 1.2% of the variance was shared).
Discussion
The purpose of this study was to develop a new cancer
worry questionnaire, the Assessment of Survivor Concerns
(or ASC). Previously, measures specific to this construct
have been either included as part of a larger scale, or not
vigorously tested for reliability and validity. Our objective
was to keep the instrument simple and easy to use, and we
therefore developed six items with three specific to cancer
worry, and three applying to general health worry. Our
assessments of reliability and validity for the question-
naire have shown that, in its present form, the ASC instru-
ment is well-suited for research in which a cancer
concerns measure is needed. Construct validity was dem-
onstrated through confirmatory factor analysis and
through examinations of convergent and discriminant
validity. Additionally, the instrument was shown to be
invariant across two important cancer survivor groups,
short- and long-term survivors. This was apparent even
though there were many more short-term than long-term
survivors (592 versus 161). However, because of the rela-
tively small number of long-term survivors, extra caution
should be used in interpreting the long-term survivor
results.
While the instrument appears solid, there are areas in
need of improvement. Specifically, the health worry sub-
Table 6: Convergent and discriminant validity correlations
Original Six-Item ASC
Cancer Worry Health Worry
Validity Instrument Subscale nr p nr p
Convergent PANAS Negative 722 .34 * 722 .46 *
CES-D Total 727 .19 * 725 .39 *
Discriminant PANAS Positive 726 .11 .003 724 .06 .10
Revised Five-Item ASC (children's health item excluded)
Cancer Worry Health Worry
Validity Instrument Subscale nr p nr p
Convergent PANAS Negative 722 .34 * 721 .43 *
CES-D Total 727 .19 * 724 .39 *
Discriminant PANAS Positive 726 .11 .003 723 .02 .67
n is the sample size, r is the correlation, and p is the probability value. An asterisk (*) indicates that the p-value is less than 0.0001. Sample sizes vary 
because of missing values.Health and Quality of Life Outcomes 2007, 5:15 http://www.hqlo.com/content/5/1/15
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scale did not fare as well as the cancer worry subscale. The
health worry subscale had lower reliability and was not
robust under different missing value deletion methods.
An issue that might have been contributing to these prob-
lems was the children's health item. Of the six question-
naire items, children's health had the lowest factor
loading and the highest number of missing values, due to
the fact that several participants in the study did not have
any children. Because of the problems with the children's
health item, we re-ran our analyses with this item
excluded, and the results showed no detrimental effect to
the validity of the ASC. Hence, it is our recommendation
that the revised five-item ASC be used instead of the orig-
inally proposed six-item instrument. Alternatively, if
researchers do not need the health worry subscale, it can
be excluded, with only the three-item cancer worry sub-
scale used.
We should note that the results presented here might not
generalize to cancer populations with older, less educated,
and lower income individuals because those individuals
were more likely to skip items. We should also note that
the ASC does not include many other worries that cancer
survivors – and particularly specific subgroups – may
experience. For example, young cancer survivors may be
worried about whether or not their fertility has been
affected by cancer treatment. Additional questionnaires
are needed for concerns other than those related to recur-
rence and general health.
It is interesting that our results are consistent with those of
Avis, et al. [8] (which we were not aware of when conduct-
ing this study). Their questionnaire includes a four-item
distress-recurrence factor comprising four items (worry
about cancer coming back, worried that pain indicates
cancer, worried about dying from cancer, preoccupied
with cancer concerns). There are some differences in our
findings–the ASC items about death and health made up
a separate health worry factor, and the other three items
comprised a specific cancer worry factor. However, there is
specific overlap in one item and similar levels of factor
loadings. Our study included a much larger sample, and a
majority of short-term survivors, in contrast to Avis, et.
al.'s inclusion of only long-term survivors. Thus, it is
encouraging that the construct and measurement of survi-
vor concerns is reasonably robust across investigators and
survivor participants.
Conclusion
In conclusion, we recommend the revised five-item ASC
instrument when an assessment of cancer survivor con-
cerns is needed. The ASC has excellent internal consist-
ency and validity, and is appropriate in both short-term
and long-term survivor populations.
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